European Pharmaceutical Review

JANUARY 26, 2023

Through the Cancer Drugs Fund (CDF), in 2018, England was the first European country to provide access to a CAR T-cell therapy to treat these blood cancers. Since then, over 500 patients in England have received axi-cel. CAR T-cell therapy engineers a patient’s own immune cells (T-cells) to detect, target and destroy cancer cells.

Chemotherapy 120

Chemotherapy Immunization 120

pharmaphorum

MAY 26, 2022

The co-founder of Los Angeles biotech Enochian Biosciences has been arrested in connection with a federal investigation into the murder of a Vermont man in 2018. The Department of Justice said that Banks is suspected of kidnapping Gregory Davis from his Danville home on 6 January, 2018 and carrying out his murder.

Chemotherapy 104

Chemotherapy 104

Pharmaceutical Technology

JUNE 1, 2023

The PROpel study included 796 mCRPC patients who had not received prior chemotherapy or NHAs in the mCRPC setting. Trials peaked at 115 in 2018 before declining to 91 last year. Safety and tolerability were in line with that observed in prior trials and the known profiles of the medicines. So far, 68 trials have been initiated in 2023.

FDA 97

FDA Chemotherapy 97

Pharmaceutical Technology

MARCH 6, 2023

Patients in the US and EU with recurrent or metastatic nasopharyngeal carcinoma (NPC), a subtype of head and neck squamous cell carcinoma (HNSCC), are mostly treated with a combination of chemotherapy agents in the frontline setting, such as cisplatin + gemcitabine. months for the chemotherapy arm (hazard ratio [HR]: 0.52).

Chemotherapy 52

Chemotherapy FDA Labelling Immunization 52

European Pharmaceutical Review

SEPTEMBER 29, 2023

Janssen Pharmaceutical Companies of Johnson & Johnson’s Phase III MARIPOSA study is the first to show a clinically meaningful benefit in a chemotherapy-free regimen compared to the small molecule treatment TAGRISSO ® ( osimertinib ).

Pharmaceutical Companies 104

Pharmaceutical Companies Pharmaceutical Companies Chemotherapy Immunization 104

pharmaphorum

JUNE 13, 2022

Data from the QuANTUM-First trial presented at the EHA congress showed that quizartinib more than doubled the median overall survival when added to first-line chemotherapy in patients with newly-diagnosed, FLT3-ITD-positive acute myeloid leukaemia (AML). Quizartinib plus standard chemotherapy reduced the risk of death by 22.4%

Chemotherapy 97

Chemotherapy FDA 97

pharmaphorum

SEPTEMBER 6, 2022

The Nijmegen, Netherlands-based biotech was founded in 2018 to develop therapies designed to change the balance of protein expression within the tumour ‘microenvironment’, which can defend cancers against the immune system, and is increasingly becoming a source of new targets in oncology. The Series A round includes €3.6

Chemotherapy 102

Chemotherapy Immunization FDA 102

pharmaphorum

AUGUST 4, 2021

The HDAC inhibitor was given an accelerated approval by the FDA as a second-line PTCL therapy on the strength of overall response data, but a phase 3 study comparing Istodax to first-line chemotherapy showed no improvement on progression-free survival (PFS).

FDA 98

FDA Chemotherapy Labelling 98

pharmaphorum

AUGUST 3, 2022

Ipsen and Servier’s hopes of extending the uses for chemotherapy drug Onivyde have been knocked back by a failed phase 3 trial of the drug as a second-line therapy for small cell lung cancer (SCLC). billion in 2018. million) in sales for the product in the first six months of this year, a rise of 30% at constant exchange rates.

Chemotherapy 52

Chemotherapy FDA 52

pharmaphorum

AUGUST 11, 2022

Pluvicto (lutetium (177Lu) vipivotide tetraxetan) has been cleared for adults with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) who have been previously treated with androgen receptor inhibitors and taxane-based chemotherapy or not medically suitable for taxane drugs. After a median follow-up of 20.9

Chemotherapy 62

Chemotherapy FDA 62

pharmaphorum

SEPTEMBER 30, 2021

That data has now been review, and NICE has upgraded Tecentriq (atezolizumab) to full NHS access for patients with advanced UC who have not received treatment before but cannot have cisplatin-based chemotherapy, and whose tumours have a PD-L1 expression of 5% or more.

Chemotherapy 52

Chemotherapy 52

pharmaphorum

OCTOBER 14, 2021

Keytruda (pembrolizumab) can be used in combination with chemotherapy, with or without bevacizumab, to treat patients with persistent, recurrent or metastatic cervical cancer where the tumour expresses a certain level of PD-L1. 0.77]; p<0.0001) compared to chemotherapy, with or without bevacizumab, where tumours expressed PD-L1 (CPS ?

Chemotherapy 44

Chemotherapy Research Laboratories Immunization FDA 44

Hospital Pharmacy Europe

FEBRUARY 23, 2023

A significant 5-year overall survival rate has been found following neoadjuvant nivolumab therapy in resectable non-small cell lung cancer According to a global 2018 study, lung cancer was the most commonly diagnosed cancer (11.6% The patient cohort was derived from the team’s earlier 2018 trial described above.

Hospitals 97

Hospitals Chemotherapy 97

pharmaphorum

OCTOBER 6, 2022

The strategy to build in cancer dates back to 2015, and has since gathered momentum with the purchase of the oncology businesses of Shire and Agios Pharma in 2018 and 2020, for $2.4 billion and $1.8 billion respectively, as well as smaller deals such as its takeover of Danish antibody specialist Symphogen.

Generic Medicine 98

Generic Medicine Chemotherapy 98

pharmaphorum

APRIL 11, 2022

In the VISION study reported at ASCO last year, Pluvicto given on top of standard care reduced the risk of death by 38% compared to standard care alone in men with PSMA+ mCRPC who had progressed after three or more prior anti-androgen and chemotherapy regimens. The drug was the lead asset in Novartis’ $2.1

Chemotherapy 52

Chemotherapy 52

pharmaphorum

NOVEMBER 10, 2022

In June, Clovis suffered another blow when it withdrew Rubraca’s mCRPC approval, after a post-marketing trial showed a higher death rate with the drug compared to chemotherapy when used as a third- or later-line treatment for the cancer.

Chemotherapy 57

Chemotherapy Labelling FDA 57

pharmaphorum

APRIL 27, 2021

On Wednesday (28 April), the focus will shift to Keytruda and Tecentriq as first-line treatments for UC patients unable to be treated with cisplatin-containing chemotherapy – which got the go-ahead in 2017 and 2018, respectively. The post FDA looks at pulling speedy approvals for three cancer drugs appeared first on.

FDA 90

FDA Chemotherapy Documentation 90

pharmaphorum

JUNE 7, 2021

” J&J paid Argenx a hefty $300 million upfront to secure rights to cusatuzumab (also known as JNJ-4550) in December 2018, and also made a $200 million equity investment in the Belgian company as part of a deal that had a total value of $1.6

Chemotherapy 62

Chemotherapy Immunization 62

European Pharmaceutical Review

JULY 5, 2022

The availability of oral chemotherapy treatments would provide stomach cancer patients with the option of more efficacious drugs with improved tolerability in a more convenient dosage format” The poor clinical outcomes of stomach cancer make it a key target for drug development. Benefits of daily oral chemotherapy over IV.

Chemotherapy 85

Chemotherapy Dosage Labelling Compounding 85

pharmaphorum

JUNE 4, 2021

Giving Lynparza (olaparib) to women with BRCA-positive, HER2-negative breast cancer straight after chemotherapy and surgery to remove the tumour reduced the risk of recurrence, secondary cancers or death by 42% compared to placebo after 2.5 years of follow-up.

Chemotherapy 98

Chemotherapy Labelling 98

pharmaphorum

MARCH 24, 2022

In the VISION study reported at ASCO last year, Pluvicto given on top of standard care reduced the risk of death by 38% compared to standard care alone in men with PSMA+ mCRPC who had progressed after three or more prior anti-androgen and chemotherapy regimens. After a median follow-up of 20.9 months, compared to 3.4 months, respectively.

Chemotherapy 57

Chemotherapy Labelling FDA 57

pharmaphorum

JUNE 23, 2021

Keytruda (pembrolizumab) was given an accelerated approval in 2018 as a second-line therapy for PD-L1-positive cervical cancer, but the new survival data – from the phase 3 KEYNOTE-826 trial – could extend the use of the drug. The post In a class first, Merck’s Keytruda extends survival in cervical cancer appeared first on.

Chemotherapy 84

Chemotherapy FDA Labelling 84

pharmaphorum

MARCH 15, 2021

A phase 3 trial of the PD-1 inhibitor in cervical cancer patients who had progressed after first-line chemotherapy has been stopped early after an interim look at the data showed that the drug cut mortality by 31% compared to second-line chemo. The median overall survival with Libtayo (cemiplimab) was 12 months, compared to 8.5

Chemotherapy 52

Chemotherapy Vaccines 52

pharmaphorum

MARCH 18, 2021

Keytruda (pembrolizumab) was being reimbursed on an interim basis for advanced or metastatic urothelial carcinoma, following platinum based chemotherapy, by the Cancer Drugs Fund (CDF) until survival data from a larger study emerged.

Chemotherapy 52

Chemotherapy Documentation 52

pharmaphorum

JUNE 4, 2021

New data from the VISION study showed that 177Lu-PSMA-617 on top of standard care reduced the risk of death by 38% compared to standard care alone in men with PSMA-positive metastatic castration-resistant prostate cancer (CRPC) who had progressed after three or more anti-androgen and prior chemotherapy regimens.

Chemotherapy 88

Chemotherapy 88

pharmaphorum

JANUARY 5, 2021

Roche’s drug is already FDA-approved as a monotherapy and in combination with Avastin (bevacizumab) and chemotherapy for previously-untreated NSCLC with high PD-L1 expression.

Chemotherapy 52

Chemotherapy Immunization FDA Labelling 52

Pharmaceutical Technology

SEPTEMBER 26, 2022

It provides a further valuable treatment option that can increase the time they remain in good health and delay the need for chemotherapy and its associated side effects. “As In addition to palbociclib, NICE has granted approval for 15 other therapies for breast cancer since 2018.

Chemotherapy 52

Chemotherapy 52

pharmaphorum

MARCH 25, 2022

AstraZeneca’s hopes of developing its PD-L1 inhibitor Imfinzi for cervical cancer have been hit by a failed phase 3 trial of the drug alongside chemotherapy as a first-line treatment for women with locally-advanced tumours.

Chemotherapy 98

Chemotherapy 98

Pharmaceutical Technology

MAY 12, 2023

The agent is a human epidermal growth factor receptor 2 (HER2)-targeting ADC that utilises Eisai’s chemotherapy Halaven (eribulin) as its payload. Eisai signed a licensing agreement with BlissBio in 2018 for the Chinese companies’ exclusive right to use eribulin as their ADC payload.

Chemotherapy 64

Chemotherapy Compounding 64

pharmaphorum

OCTOBER 19, 2020

The combination therapies had previously been marketed following accelerated approval in November 2018 on the basis of early stage results. The drug’s US label also covers certain patients with chronic lymphocytic leukaemia, including a chemotherapy-free regimen for previously untreated patients.

Adverse Reactions 57

Adverse Reactions FDA Chemotherapy Labelling 57

pharmaphorum

AUGUST 4, 2022

The CRPC trial – KEYNOTE-921 – looked at the combination of Keytruda (pembrolizumab) with docetaxel in more than 1,000 patients who had not been treated with chemotherapy before, but who had seen disease progression despite earlier treatment with an anti-hormonal therapy.

Chemotherapy 104

Chemotherapy Labelling FDA 104

pharmaphorum

NOVEMBER 12, 2020

Shares in US biotech Five Prime Therapeutics more than tripled after it reported promising trial results with stomach cancer drug candidate bemarituzumab, returning the stock to levels not seen since 2018. In the study, the median PFS improved from 7.4 months to 9.5 Median overall survival was 12.9

Chemotherapy 52

Chemotherapy Immunization 52

The Checkup by Singlecare

APRIL 14, 2024

Certain supplements, flea medications, and chemotherapy drugs may also cause adverse reactions. However, they also say some research has shown toxicity at lower doses, such as this 2018 study , which recommended caution with doses greater than 40 mg/kg/day. How much metronidazole can I give my dog?

Dosage 98

Dosage Adverse Reactions Chemotherapy Labelling 98

pharmaphorum

FEBRUARY 17, 2021

At an interim analysis, Lynparza (olaparib) reduced recurrence of disease compared to placebo in women with BRCA-mutated, HER2-negative breast cancer after surgery and chemotherapy to remove the tumour.

Chemotherapy 57

Chemotherapy 57

pharmaphorum

NOVEMBER 18, 2021

The company is also looking at applications including pain during childbirth or trauma, or tackling the discomfort caused by some treatments such as cancer chemotherapy. Lower back pain is one of the top causes of disability around the world, and according to a 2018 report in The Lancet accounts for 189 million lost working days and $62.4

FDA 98

FDA Chemotherapy 98

pharmaphorum

DECEMBER 6, 2022

Ezutromid was abandoned in 2018 on phase 2 data, with Summit turning its attention ridinilazole only for the drug to miss the mark in a phase 3 study reported earlier this year, leaving the company with early-stage antibiotic and oncology projects.

Chemotherapy 52

Chemotherapy Immunization 52

pharmaphorum

NOVEMBER 10, 2020

It’s the second time that the SMC has rejected Veltassa (patiromer), having previously turned it down for hyperkalaemia in 2018. The SMC’s verdict creates a divergence in access to Veltassa in the UK as NICE cleared the drug for use by NHS England at the end of 2019, after also rejecting it in 2018.

Dosage 52

Dosage Chemotherapy 52